disease the larger the size or proportion of the genome, so were also thought to have high certainty in counseling. Rare CNVs were individually examined to determine their likelihood of having an affected phenotype. RESULTS: There were 970 prenatal CMAs performed. Of these, 58 (6.0%) were categorized as a VUS. The number in each category is shown in Table 1 . Among the 58 VUSs, 33 (56.9%) were associated with a known phenotype, and 56 (96.6%) were associated with a high level of certainty regarding the likelihood of an affected phenotype. CONCLUSION: Most VUSs (96.6% of all VUSs, 99.8% of all CMAs) were associated with a high level of certainty regarding the likelihood of an affected phenotype. Variants of truly uncertain significance are relatively uncommon, and most cases can be categorized as to the potential risk of an affected phenotype and what phenotypes are possible.
OBJECTIVE: Platinum-based chemotherapy, such as carboplatin and more commonly cisplatin damage tiny hair cells in the inner ear that vibrate in response to sound waves. The National Cancer Institute reports at least 50% of children have permanent hearing loss after treatment. The incidence of hearing loss after in utero exposure to chemotherapy is unknown. STUDY DESIGN: The Cancer and Pregnancy Registry, established in 1997, follows women diagnosed with cancer during pregnancy and continues annually for both mother and child after delivery. Children with hearing loss were identified in relation to maternal cancer type, stage and treatment during pregnancy. RESULTS: Four children were identified as having hearing loss, including sensorineural hearing loss (3) and enlarged vestibular aqueducts (2). Two have bilateral hearing aids. One child was a member of a twin gestation, and the other twin has normal hearing. Mean maternal age at diagnosis was 34.6 +/-SD 5.9 years. Mean gestational age (GA) at diagnosis was 15.7 weeks. Cancer types included: Ovarian (2), Chronic Leukemia (1), and Cervical (1) cancer. Three children were exposed to chemotherapy in utero, 1 to alpha interferon. Seventy five percent (3/4) of cases with hearing loss in childhood were exposed to a platinum agent in pregnancy. Regimens: Cisplatin/Paclitaxel(1), Etoposide/Cisplatin/Bleomycin(1), and Carboplatin/Paclitaxel(1). Mean GA at first treatment was 22.1+/-SD 4.8weeks. Mean number of treatment cycles in pregnancy was 3.6 +/-1. Mean GA at delivery was 35.7 +/-3.7 weeks. The mean birth weight was 2,554.6 +/-625.12 grams. 16 additional children were exposed to cisplatin and 7 to carboplatin in utero without hearing loss. There were no statistical differences in the cancer stage, maternal age at diagnosis, number of treatment cycles, GA at the first treatment, GA at birth, birthweight or use of postnatal antibiotics between the affected and unaffected groups. CONCLUSION: Approximately 15.7% of children exposed to Cisplatin and 12.5% exposed to Carboplatin in utero were diagnosed with hearing loss in early childhood. Integrated Genetics, Cypress, CA OBJECTIVE: To assess the frequency of chromosomal aneuploidy in the intrauterine growth restricted (IUGR) fetus without major structural anomalies. STUDY DESIGN: A retrospective analysis utilizing a reference lab database was performed for patients undergoing invasive prenatal testing between 2011 and 2017. Inclusion criteria included the documented indication for testing of IUGR. Women with major structural malformations noted on ultrasound were excluded from analysis. We analyzed the frequency of varying types of aneuploidy in our cohort, and performed a subanalysis comparing aneuploidy results for fetuses with ultrasonographic soft markers to those without soft markers. RESULTS: There were 1802 patients without major structural abnormalities having invasive diagnostic procedures with IUGR as the indication for testing. There were 152 (8.5%) chromosomally abnormal fetuses. Of the chromosomally abnormal fetuses, there were 72 cases of Trisomy 18 (47.3 %), 6 cases of Trisomy 13 (3.9 %), and 20 cases of Trisomy 21 (13.2%). Partial deletion and duplication syndromes accounted for 28 cases (18.4%), triploidy accounted for 21 cases (13.8%), and other rare anomalies constituted 5 cases (3.2%). When fetuses with ultrasonographic soft markers were excluded, there were 98/1595 (6.2%) chromosomally abnormal fetuses. There was a statistically significant higher proportion of chromosomally abnormal IUGR fetuses when ultrasonographic soft markers were present 54/207 (26.1%) when compared to the proportion of chromosomally abnormal IUGR fetuses without any soft markers 98/1595 (6.2%), p<0.00001. CONCLUSION: Fetuses with isolated IUGR and no major structural abnormalities have a significant risk of aneuploidy. Our data suggests that patients with isolated IUGR should be offered diagnostic testing for chromosomal assessment. Further prospective studies are needed to delineate the utility of chromosomal microarray, whole exome sequencing, and cfDNA in the assessment and etiopathogenesis of the fetus with isolated IUGR.
883 Copy neutral changes identified by SingleNucleotide Polymorphism (SNP) microarray analysis during prenatal diagnosis OBJECTIVE: To assess the clinical impact of copy neutral changes detected by single-nucleotide polymorphism (SNP) microarray analysis during prenatal diagnosis. STUDY DESIGN: A retrospective review was performed on amniotic fluid specimens from one prenatal diagnosis center and patients with copy neutral changes were identified on SNP microarray analysis. Clinical impacts including further testing options and patient decisions were evaluated. RESULTS: Twelve cases with isolated copy neutral changes were identified among a total of 443 amniotic fluid specimens (2.7%) sent for SNP microarray analysis. There were four cases with an increased number of short contiguous runs of regions of homozygosity (ROH) associated with an isolated population, two cases of long ROH in chromosomes 7 and 14 suggesting possible uniparental disomy (UPD), and six cases with long stretches of ROH in multiple chromosomes indicating identity by descent. Four of the cases had further analysis performed through an online ROH analysis tool in an attempt to identify recessive genes in the ROH region that were associated with specific ultrasound findings seen in the fetuses and positive results were seen in two cases. Two genes associated with cleft lip were identified in one case and one gene associated with clubfeet was found in the other case. In both cases, further genetic testing options were offered and the patients declined to proceed. UPD was ruled out in the case with possible UPD 14 and the patient declined UPD testing on the case with a possible UPD 7. After being informed of the microarray results and the significance of the ROH findings, all patients opted to continue with the pregnancy except one, who terminated due to severe abnormal ultrasounds findings and poor prognosis of the fetus. Of the pregnancies continued, one patient had a fetal demise at 22 weeks and another patient was induced at 29 weeks due to holoprosencephaly. CONCLUSION: Copy neutral changes were seen in 2.7% of patients in our study. The identification of these changes provided more testing options for the patients and helped patients make better informed decisions. Due to the complexity of these findings, genetic counseling is important. Detection of copy neutral changes did not seem to change pregnancy decisions in our small patient population.
884 Need to know: A pilot study to evaluate informed consent of current prenatal aneuploidy screening Maternal-Fetal Medicine, University of Illinois at Chicago., Chicago, IL OBJECTIVE: Prenatal aneuploidy testing requires complex counseling as recommended by ACOG. Decision making is complicated and little is known about patients' understanding of prenatal aneuploidy testing. This pilot study sought to investigate patients' knowledge and understanding of this testing. STUDY DESIGN: A self-directed survey was offered to pregnant women between 20-40 weeks gestational age (GA) at the University of Illinois at Chicago. The 21 question survey focused on knowledge and understanding of aneuploidy testing, testing options, how subjects chose their test, and results they received. Survey data were then compared with information extracted from medical records regarding each subject's aneuploidy testing type and result.
Qualitative analysis was done on SPSS using descriptive statistics and bivariate analysis. RESULTS: From October 2017 to February 2018, 67 eligible women participated in the survey. Only 41 subjects (62%) accurately knew the results of their aneuploidy testing, 30(44.7%) recalled being told testing was optional, and 51 (76%) did not correctly remember the type of test they had. Abnormal test results did not improve recall; only 1 of the 6 subjects (16%) with abnormal tests accurately recalled their results. Twenty-five subjects (37%) said they chose the type of testing and only 21 (31%) recalled being told the testing was optional. Level of education did not affect recall. Subjects with high school (HS) degree or less were and those with higher degrees were similar in knowing their test results (10 of 21, 48% vs 31 of 46, 69%, p ¼ .97). Women with HS degree or less were less likely to correctly answer knowledge questions about screening tests (8 of 21, 38%% vs 29 of 46, 63%, p ¼.012). MFM clinic patients had the highest accurate recall of their results (23 of 32, 70%). Ethnicity, age and gestational age were not associated with accuracy in test result recall. CONCLUSION: Despite current professional recommendations which stress the importance of counseling and consent for prenatal aneuploidy testing, our results show pregnant women have poor recollection of this counseling, including the test they chose and the correct result. These findings suggest patients need better counseling and guidance through the antenatal aneuploidy testing process.
